AKT1 and thyroid gland papillary carcinoma: Recently it was also shown that in papillary thyroid carcinoma crizotinib acts as a antitumor agent by inhibiting phosphorylation of MET, AKT and its downstream signaling molecules and synergizes with TRAIL in suppression of tumor growth22.